[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5818 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 5818

 To amend title XVIII of the Social Security Act to expand coverage of 
  the in-home administration of intravenous immune globulin under the 
                           Medicare program.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           September 28, 2023

 Mr. Smith of Nebraska (for himself and Mr. Garamendi) introduced the 
   following bill; which was referred to the Committee on Energy and 
  Commerce, and in addition to the Committee on Ways and Means, for a 
 period to be subsequently determined by the Speaker, in each case for 
consideration of such provisions as fall within the jurisdiction of the 
                          committee concerned

_______________________________________________________________________

                                 A BILL


 
 To amend title XVIII of the Social Security Act to expand coverage of 
  the in-home administration of intravenous immune globulin under the 
                           Medicare program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Medicare IVIG Access Enhancement Act 
of 2023''.

SEC. 2. EXPANDING COVERAGE OF THE IN-HOME ADMINISTRATION OF INTRAVENOUS 
              IMMUNE GLOBULIN UNDER THE MEDICARE PROGRAM.

    (a) In General.--Section 1861 of the Social Security Act (42 U.S.C. 
1395x) is amended--
            (1) in subsection (s)(2)(Z), by inserting ``(and, beginning 
        January 1, 2026, for the treatment of chronic inflammatory 
        demyelinating polyneuropathy and multifocal motor neuropathy)'' 
        after ``primary immune deficiency diseases''; and
            (2) in subsection (zz), by inserting ``(or, beginning 
        January 1, 2026, with diagnosed chronic inflammatory 
        demyelinating polyneuropathy and multifocal motor neuropathy)'' 
        after ``primary immune deficiency disease''.
    (b) Authority for Variance in Payments.--Section 1842(o)(8) of the 
Social Security Act (42 U.S.C. 1395u(o)(8)) is amended by inserting 
``and may vary depending on whether such administration is related to 
treatment of a primary immune deficiency disease or the treatment of 
chronic inflammatory demyelinating polyneuropathy or multifocal motor 
neuropathy (as determined appropriate by the Secretary through notice 
and comment rulemaking)'' after ``of 2012''.
                                 <all>